MX2023007574A - "vacuna de arn contra variantes de sars-cov-2. - Google Patents

"vacuna de arn contra variantes de sars-cov-2.

Info

Publication number
MX2023007574A
MX2023007574A MX2023007574A MX2023007574A MX2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A
Authority
MX
Mexico
Prior art keywords
nucleic acid
cov
infection
coronavirus
variants
Prior art date
Application number
MX2023007574A
Other languages
English (en)
Spanish (es)
Inventor
Nicole Roth
Susanne Rauch
Hans Wolfgang Grosse
Diego Chaves Moreno
Dominik Vahrenhorst
Original Assignee
CureVac SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/052455 external-priority patent/WO2021156267A1/en
Application filed by CureVac SE filed Critical CureVac SE
Publication of MX2023007574A publication Critical patent/MX2023007574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
MX2023007574A 2020-12-22 2021-12-21 "vacuna de arn contra variantes de sars-cov-2. MX2023007574A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063129395P 2020-12-22 2020-12-22
PCT/EP2021/052455 WO2021156267A1 (en) 2020-02-04 2021-02-03 Coronavirus vaccine
EP2021069632 2021-07-14
EP2021069626 2021-07-14
PCT/IB2021/062127 WO2022137133A1 (en) 2020-12-22 2021-12-21 Rna vaccine against sars-cov-2 variants

Publications (1)

Publication Number Publication Date
MX2023007574A true MX2023007574A (es) 2023-09-29

Family

ID=82120270

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007574A MX2023007574A (es) 2020-12-22 2021-12-21 "vacuna de arn contra variantes de sars-cov-2.

Country Status (9)

Country Link
US (3) US20240156946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267178A1 (cg-RX-API-DMAC7.html)
JP (1) JP7894882B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230164648A (cg-RX-API-DMAC7.html)
AU (1) AU2021405281A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023012303A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205569A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007574A (cg-RX-API-DMAC7.html)
WO (1) WO2022137133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021198706A2 (en) * 2020-04-01 2021-10-07 Diosynvax Ltd Coronavirus vaccines
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
CA3183351A1 (en) 2020-06-19 2021-12-23 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022246215A1 (en) * 2021-05-21 2022-11-24 Meso Scale Technologies, Llc. Viral strain serology assays
IL309502A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US12397051B2 (en) * 2021-09-14 2025-08-26 Globe Biotech Limited Vaccine for use against coronavirus and variants thereof
AU2022358982A1 (en) * 2021-10-06 2024-05-23 Diosynvax Ltd Coronavirus vaccines
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023094713A2 (en) * 2021-11-29 2023-06-01 BioNTech SE Coronavirus vaccine
CN116200403A (zh) * 2021-11-30 2023-06-02 石药集团巨石生物制药有限公司 预防突变株的新型冠状病毒mRNA疫苗
WO2023108076A1 (en) * 2021-12-08 2023-06-15 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
TW202400635A (zh) * 2022-04-20 2024-01-01 美商因諾維奧製藥公司 針對sars-cov-2變異體之免疫原性組合物及其使用方法
KR20250004901A (ko) * 2022-05-02 2025-01-08 아라미스 바이오테크놀로지스 인코포레이티드 변형된 코로나바이러스 s 단백질
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024011163A1 (en) * 2022-07-06 2024-01-11 Georgia State University Research Foundation, Inc. Coronavirus vaccines and methods of use thereof
AU2023310896A1 (en) * 2022-07-19 2025-01-30 Shenzhen Shenxin Biotechnology Co., Ltd. Mrna for sars-cov-2 s protein and use thereof
WO2024021817A1 (zh) * 2022-07-27 2024-02-01 珠海丽凡达生物技术有限公司 新型冠状病毒疫苗及其制备方法和应用
CN117467677B (zh) * 2022-07-27 2025-12-02 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗
WO2024050483A1 (en) * 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
US20260130985A1 (en) * 2022-09-23 2026-05-14 Advanced Rna Vaccine (Arv) Technologies, Inc. Nucleic acid-based universal vaccine and methods of use thereof
CA3267272A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa FLU VIRUS VACCINES
WO2024073005A2 (en) * 2022-09-28 2024-04-04 The Johns Hopkins University Exosome display compositions
WO2024067861A1 (en) * 2022-09-29 2024-04-04 Suzhou Abogen Biosciences Co., Ltd. MULTIVALENT NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 DELTA AND OMICRON STRAINS
KR102797156B1 (ko) * 2022-10-14 2025-04-22 한국화학연구원 사스 코로나바이러스 2 베타 변이주 항원 및 이를 포함하는 고효능 백신 조성물
US20240131139A1 (en) * 2022-10-25 2024-04-25 D4 Labs, Llc Adjuvanted subcutaneously-administered polypeptide sars-cov-2 vaccines composition and methods
WO2024089638A1 (en) * 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
US12589146B2 (en) 2023-02-22 2026-03-31 D4 Labs, Llc Adjuvanted protein vaccines comprising modified full-length spike protein of SARS-CoV-2 composition and methods of use
EP4669348A1 (en) * 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
KR20250175335A (ko) * 2023-04-24 2025-12-16 노바백스, 인코포레이티드 Sars-cov-2 백신 조성물
EP4701657A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
JP2026518411A (ja) 2023-04-27 2026-06-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスワクチン
WO2024232913A1 (en) * 2023-05-05 2024-11-14 D4 Labs, Llc Adjuvanted vaccines containing modified s1 spike protein of sars-cov-2 variant c.1.2 and methods of us
US11911461B1 (en) 2023-05-05 2024-02-27 D4 Labs, Llc Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use
CN121752291A (zh) * 2023-06-30 2026-03-27 思齐乐私人有限公司 SARS-CoV-2 RNA疫苗及其用途
CN117257761A (zh) * 2023-09-20 2023-12-22 莎穆(上海)生物科技有限公司 一种包载核酸的抗氧化脂质纳米粒、其制备方法及应用
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN118078978A (zh) * 2024-03-14 2024-05-28 成都威斯克生物医药有限公司 防治SARS-CoV-2变异株JN.1、BA.2.86和XBB谱系的重组蛋白疫苗、联合用药物及用途

Family Cites Families (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6134717A (en) 1998-11-20 2000-10-24 Morning Pride Manufacturing, L.L.C. Protective garment with leg portions and with cuffs to prevent liquids from entering boots
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US10188083B2 (en) 2016-08-21 2019-01-29 Daniel Michael Leo Insect production systems and methods
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
KR20070052273A (ko) 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
JP5721441B2 (ja) 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーCurevac Gmbh 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体
NZ589157A (en) 2008-04-14 2013-06-28 Corp Nuvolt Inc Detecting electrical anomalies by receiving sensor data with received anomaly detection rules
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
RU2573409C2 (ru) 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
ES2769129T3 (es) 2009-12-07 2020-06-24 Univ Pennsylvania Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2987915T3 (es) 2010-09-20 2024-11-18 Sirna Therapeutics Inc Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012054365A2 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
EP2730549A4 (en) 2011-09-08 2015-03-18 Tokuyama Corp TENSID-COATED HALF-HYDRATGIPS AND MANUFACTURING METHOD THEREFOR
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
WO2013143698A1 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
ES2660129T3 (es) 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2854857B1 (en) 2012-05-25 2018-11-28 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
MX2015011945A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
BR112016000889A2 (pt) 2013-08-21 2017-12-12 Curevac Ag composição e vacina para tratamento de câncer de próstata
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
AU2014310932B2 (en) 2013-08-21 2019-06-06 CureVac SE Composition and vaccine for treating lung cancer
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
SG11201608605QA (en) 2014-06-10 2016-12-29 Curevac Ag Methods and means for enhancing rna production
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3177732A4 (en) 2014-08-08 2018-04-25 ModernaTX, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
ES3015369T3 (en) 2014-10-09 2025-05-05 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
EP4023755B1 (en) 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
US20160188710A1 (en) 2014-12-29 2016-06-30 Wipro Limited METHOD AND SYSTEM FOR MIGRATING DATA TO NOT ONLY STRUCTURED QUERY LANGUAGE (NoSOL) DATABASE
BR112017009835A2 (pt) 2014-12-30 2017-12-26 Curevac Ag moléculas de ácido nucleico artificiais
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
EP3289077B1 (en) 2015-04-30 2020-04-15 CureVac AG Method for in vitro transcription using an immobilized restriction enzyme
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
DK3294326T3 (da) 2015-05-15 2021-05-31 Curevac Ag Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
DK3303583T3 (da) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
EP3699288A1 (en) 2015-08-07 2020-08-26 CureVac AG Process for the in vivo production of rna in a host cell
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
US12258567B2 (en) 2015-08-28 2025-03-25 CureVac SE Artificial nucleic acid molecules
WO2017046801A1 (en) 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
WO2017064146A1 (en) 2015-10-12 2017-04-20 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
JP2018530587A (ja) 2015-10-16 2018-10-18 モデルナティエックス インコーポレイテッドModernaTX,Inc. mRNAキャップ類似体およびmRNAキャッピングの方法
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
WO2017108087A1 (en) 2015-12-21 2017-06-29 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
US12612654B2 (en) 2016-02-12 2026-04-28 CureVac SE Method for analyzing RNA
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
WO2017162297A1 (en) 2016-03-24 2017-09-28 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
EP4487869A3 (en) 2016-04-22 2025-07-30 CureVac SE Rna encoding a tumor antigen
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
EP3468612A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
US20190336611A1 (en) 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
FR3056365A1 (fr) 2016-09-19 2018-03-23 Stmicroelectronics Sa Procede de gestion du fonctionnement d'un circuit de bascule synchrone de retention de faible complexite, et circuit correspondant
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MX2019011215A (es) 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
EP3625363A1 (en) 2017-05-17 2020-03-25 CureVac Real Estate GmbH Method for determining at least one quality parameter of an rna sample
US10724437B2 (en) 2017-06-28 2020-07-28 General Electric Company Systems and methods for particle separator in a gas turbine engine
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
BR112020004351A2 (pt) 2017-10-19 2020-09-08 Curevac Ag moléculas de ácido nucleico artificial
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
CN111511928A (zh) 2017-12-21 2020-08-07 库瑞瓦格股份公司 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
AU2019271215B2 (en) 2018-05-16 2024-09-12 Translate Bio, Inc. Ribose cationic lipids
US12076439B2 (en) 2018-05-24 2024-09-03 Translate Bio, Inc. Thioester cationic lipids
MA52762A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques comprenant une fraction stéroïdienne
AU2019277355A1 (en) 2018-05-30 2020-12-17 Translate Bio, Inc. Phosphoester cationic lipids
EP3802507A1 (en) 2018-05-30 2021-04-14 Translate Bio, Inc. Vitamin cationic lipids
US20210260178A1 (en) 2018-06-27 2021-08-26 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
CA3102135A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
AU2019410737A1 (en) 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
US10745919B1 (en) 2019-07-26 2020-08-18 Big Time Investment, Llc Method and apparatus for installing a staircase assembly into a building
GB2600859B (en) 2019-08-14 2024-04-03 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids
CN110647053A (zh) 2019-09-19 2020-01-03 北京智行者科技有限公司 一种自动驾驶仿真方法及系统
CA3162019A1 (en) 2019-12-20 2021-06-24 Gemma NAVARRO Lipid nanoparticles for delivery of nucleic acids
AU2021206307A1 (en) 2020-01-11 2022-09-08 Sivec Biotechnologies Llc A microbial system for production and delivery of eukaryote-translatable mRNA to eukarya
WO2021147025A1 (en) 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
WO2021151099A1 (en) 2020-01-24 2021-07-29 Aim Immunotech Inc. Therapeutic double stranded rna and methods for producing the same
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CR20220361A (es) 2020-01-27 2022-12-12 Valent Usa Llc Una composición insecticida acuosa y sus métodos de uso
CN115427073A (zh) 2020-01-28 2022-12-02 科达金尼克斯有限公司 去优化SARS-CoV-2及其方法和用途
WO2021154763A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
WO2021155760A1 (zh) 2020-02-03 2021-08-12 康希诺生物股份公司 用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用
DE202021004130U1 (de) * 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
US11241493B2 (en) * 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CN111821433B (zh) 2020-02-06 2021-06-08 深圳市瑞吉生物科技有限公司 mRNA疫苗及其合成方法、试剂盒
BR112022015565A2 (pt) 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
EP4085131A4 (en) 2020-02-10 2024-03-13 Versitech Limited AGAINST THE SARS-CORONAVIRUS 2 IMMUNOGENE COMPOSITIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO2021163222A1 (en) 2020-02-11 2021-08-19 Cytonus Therapeutics, Inc. Rapid vaccine platform
CN115515627A (zh) 2020-02-11 2022-12-23 美国政府(由卫生和人类服务部的部长所代表) SARS-CoV-2疫苗
WO2021163371A1 (en) 2020-02-12 2021-08-19 La Jolla Institute For Immunology Coronavirus t cell epitopes and uses thereof
AU2021219847A1 (en) 2020-02-12 2022-10-13 Massachusetts Institute Of Technology Field deployable CRISPR-Cas diagnostics and methods of use thereof
EP4103228A1 (en) 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
AU2021218985A1 (en) 2020-02-13 2022-08-25 Institut Pasteur Measles-vectored COVID-19 immunogenic compositions and vaccines
CN113186203B (zh) 2020-02-13 2022-12-30 斯微(上海)生物科技股份有限公司 治疗或者预防冠状病毒病的疫苗试剂
EP4103230A1 (en) 2020-02-14 2022-12-21 University of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
CA3167052A1 (en) 2020-02-14 2021-08-19 Mary Jo Hauser Vaccines and uses thereof to induce an immune response to sars-cov2
BR112022015666A2 (pt) 2020-02-14 2022-09-27 Etherna Immunotherapies Nv Vacinas intranasais de mrna
BR112022016054A2 (pt) 2020-02-14 2022-10-11 Altimmune Inc Composições imunogênicas para coronavírus e usos das mesmas
WO2021163456A1 (en) 2020-02-14 2021-08-19 Epivax, Inc. T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
GB202004007D0 (en) 2020-03-19 2020-05-06 Immodulon Therapeutics Ltd Coronavirus
CN111228475A (zh) 2020-02-21 2020-06-05 赛诺(深圳)生物医药研究有限公司 用于预防新型冠状病毒的生物制品
WO2021000968A2 (zh) 2020-02-23 2021-01-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN112300251B (zh) 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
CN111333704B (zh) 2020-02-24 2021-01-12 军事科学院军事医学研究院微生物流行病研究所 新型冠状病毒covid-19疫苗、制备方法及其应用
CA3178344A1 (en) 2020-03-31 2021-10-07 The Trustees Of The University Of Pennsylvania Universal influenza vaccine using nucleoside-modified mrna
CN111647053A (zh) 2020-04-16 2020-09-11 军事科学院军事医学研究院生命组学研究所 多肽及其在新型冠状病毒检测、抗体或疫苗筛选中的应用
US20230364219A1 (en) 2020-04-16 2023-11-16 Glaxosmithkline Biologicals Sa Sars cov-2 spike protein construct
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
EP4139616A1 (en) 2020-04-22 2023-03-01 Pfizer Inc. Coronavirus vaccine
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
PH12022500020A1 (en) * 2020-05-08 2024-05-06 Vir Biotechnology Inc Antibodies against sars-cov-2
CN111518175B (zh) 2020-05-11 2021-02-26 广东珩达生物医药科技有限公司 Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
KR20230009445A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나바이러스 스파이크 단백질 융합 단백질
CA3178115A1 (en) 2020-05-19 2021-11-25 Roman YELENSKY Sars-cov-2 vaccines
CN111606980B (zh) 2020-05-27 2021-10-26 中国医学科学院基础医学研究所 Sars-cov冠状病毒s2蛋白多肽及其应用
CN111606981B (zh) 2020-05-27 2022-02-08 中国医学科学院基础医学研究所 Sars-cov冠状病毒s1蛋白多肽及其应用
WO2021242294A1 (en) 2020-05-28 2021-12-02 Sotira Covid, Llc Peptides for covid-19 prevention and treatment
AU2021279079A1 (en) 2020-05-29 2022-12-15 Board Of Regents, The University Of Texas System Engineered coronavirus spike (s) protein and methods of use thereof
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
CN111732638B (zh) 2020-07-02 2022-01-25 重庆博唯佰泰生物制药有限公司 一种针对SARS-CoV-2的疫苗
CN111778264B (zh) 2020-07-14 2021-06-29 广州佰芮慷生物科技有限公司 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗
CN112390863B (zh) 2020-09-23 2022-11-01 厚朴生物科技(苏州)有限公司 改造的新冠病毒Spike蛋白胞外结构域及其应用
CN112266411B (zh) 2020-09-25 2022-06-24 北京诺思兰德生物技术股份有限公司 一种新型冠状病毒疫苗及其应用
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
CN112226445B (zh) 2020-10-20 2021-05-11 成都欧林生物科技股份有限公司 编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
WO2022110099A1 (en) 2020-11-30 2022-06-02 Guangzhou Argorna Biopharmaceuticals Co., Ltd. Coronavirus vaccines and uses thereof
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
WO2022180219A1 (en) 2021-02-25 2022-09-01 Kosmatopoulos Kostantinos Kostas Optimized vaccine to elicit a t cell immunity against sars-cov-2
WO2023051701A1 (zh) 2021-09-29 2023-04-06 成都威斯津生物医药科技有限公司 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
WO2023064907A1 (en) 2021-10-15 2023-04-20 Yale University Compositions and methods for vaccination against pathogenic coronavirus species and variants
US20250000968A1 (en) 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen

Also Published As

Publication number Publication date
US20220331422A1 (en) 2022-10-20
KR20230164648A (ko) 2023-12-04
US11872280B2 (en) 2024-01-16
US20240156946A1 (en) 2024-05-16
US20220202930A1 (en) 2022-06-30
AU2021405281A1 (en) 2023-07-06
AU2021405281A9 (en) 2024-08-01
JP7894882B2 (ja) 2026-07-24
US11918643B2 (en) 2024-03-05
WO2022137133A1 (en) 2022-06-30
CA3205569A1 (en) 2022-06-30
JP2024502210A (ja) 2024-01-17
BR112023012303A2 (pt) 2024-02-15
EP4267178A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ZA202406805B (en) Coronavirus vaccine
BR112023012303A2 (pt) Vacina de rna contra variantes de sars-cov-2
WO2022043551A3 (en) Multivalent nucleic acid based coronavirus vaccines
MX2022015132A (es) Vacunas combinadas a base de acidos nucleicos.
ZA202300260B (en) Stabilized coronavirus spike (s) protein immunogens and related vaccines
WO2021191630A8 (en) Coronavirus vaccine
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
MX2020010941A (es) Moleculas y composiciones novedosas de arn de vsr para vacunacion.
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
EP4477662A3 (en) Nucleic acid molecules and uses thereof
BR112022015626A2 (pt) Composição e métodos de vacinas de mrna contra infecção de novo coronavírus
SA521430813B1 (ar) لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها
WO2018115507A3 (en) Henipavirus vaccine
MX2022002611A (es) Agente farmaceutico y metodo de utilizacion del mismo para inducir inmunidad especifica contra el virus de sindrome respiratorio agudo grave sars-cov-2 (variantes).
BR112023020798A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
MX381132B (es) Vacuna contra parvovirus porcino.
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
MX2025003572A (es) Vacunas contra el virus de la influenza
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR112021019845A2 (pt) Composições de vírus inativado e formulações de vacina contra zika
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
BR112022020871A2 (pt) Agentes imunoestimuladores em combinação com inibidores da angiogênese